Mepolizumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mepolizumab |
| DrugBank ID | DB06612 |
| Brand Names (EU) | Nucala |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.66% |
Approved Indication (EMA)
Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older . Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Eosinophilic granulomatosis with polyangiitis (EGPA)Nuca
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | thrombocytopenia due to immune destruction | 99.66% | DL |
| 2 | primary release disorder of platelets | 99.61% | DL |
| 3 | pseudo-von Willebrand disease | 99.44% | DL |
| 4 | autoimmune thrombocytopenic | 99.33% | DL |
| 5 | Glanzmann thrombasthenia | 99.28% | DL |
| 6 | Evans syndrome | 98.62% | DL |
| 7 | neonatal thrombocytopenia | 98.60% | DL |
| 8 | autosomal thrombocytopenia with normal platelets | 98.37% | DL |
| 9 | filariasis | 97.67% | DL |
| 10 | mixed-type autoimmune hemolytic anemia | 96.57% | DL |
| 11 | drug-induced autoimmune hemolytic anemia | 96.38% | DL |
| 12 | cyclic hematopoiesis | 96.29% | DL |
| 13 | proteinuria | 95.91% | DL |
| 14 | syndromic constitutional thrombocytopenia | 95.86% | DL |
| 15 | neonatal autoimmune hemolytic anemia | 95.81% | DL |
| 16 | paroxysmal nocturnal hemoglobinuria | 95.48% | DL |
| 17 | fetal and neonatal alloimmune thrombocytopenia | 95.28% | DL |
| 18 | hemorrhagic disorder due to a constitutional thrombocytopenia | 94.59% | DL |
| 19 | bleeding diathesis due to a collagen receptor defect | 94.41% | DL |
| 20 | Scott syndrome | 94.36% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.